Individuals
Businesses
Company
Intelligence
News
African Capital Markets
EnglishEnglish
share on twittershare on linkedinshare on facebookshare to whatsapp
share on mail
share on instagram

Medical cannabis firm Cilo Cybin completes JSE SPAC listing

Daba Finance/Medical cannabis company Cilo Cybin completes JSE SPAC listing
AFRICAN STOCKS AND FINANCEJune 25, 2024 at 12:50 PM UTC

TLDR

  • Cilo Cybin Holdings listed on JSE AltX as Cannabis SPAC for biotech and medical cannabis acquisitions.
  • First Cannabis SPAC on AltX targeting expansion in biotechnology and medical cannabis sectors.
  • Cilo Cybin Pharmaceutical holds licenses for medical cannabis cultivation and manufacturing, producing GMP cannabis products for local and global markets.

Medical cannabis investment company, Cilo Cybin Holdings, has been listed on the Johannesburg Stock Exchange’s (JSE) AltX Board as a Special Purpose Acquisition Company (SPAC). The company aims for significant expansion and growth through new acquisitions in the biotechnology and medical cannabis industries.

Cilo Cybin is the first Cannabis SPAC to list on the AltX Board. Its first target, Cilo Cybin Pharmaceutical, is widely recognized as the first entity in South Africa to obtain both medical cannabis cultivation and manufacturing licenses. 

Cilo Cybin Pharmaceutical produces and supplies Good Manufacturing Practice (GMP) medical cannabis products, including GMP CBD, CBG, CBN isolates, and GMP THC and CBD distillates, to both local and international markets.

Key Takeaways

A SPAC is created and listed on a stock exchange with the specific goal of raising funds through an Initial Public Offering (IPO) to purchase one or more established companies or assets. By listing as a SPAC, Cilo Cybin Holdings Limited aims to secure its first target asset – the Cilo Cybin Pharmaceutical business and its 2,500-square-meter facility in Midrand. Once this acquisition is complete, the strategy is to transition to the JSE Main Board and subsequently pursue additional growth avenues, both organically and through further acquisitions. Cilo Cybin Holdings Limited is offering only 10% of its total equity, with over 71 million ordinary shares priced at R1 per share.

SPAC
JSE
Stocks
Cilo Cybin Holdings
South Africa
Finance
Investments
Capital Markets

Think someone else should see this?

share on twittershare on linkedinshare on facebookshare to whatsapp
share on mail
share on instagram
Stay informed with our newsletters read by 25,000+ professionals worldwide
Newsletter companiesNewsletter companiesNewsletter companiesNewsletter companiesNewsletter companiesNewsletter companies

Next Frontier

Stay up to date on major news and events in African markets. Delivered weekly.

Pulse54

UDeep-dives into what’s old and new in Africa’s investment landscape. Delivered twice monthly.

Events

Sign up to stay informed about our regular webinars, product launches, and exhibitions.

+25k investors have already subscribed

To invest in this opportunity and other opportunities across Africa

Download the daba finance app on your mobile through
appstore iconappstore icon
Phone Image

Take action.

Download app

Start investing in Africa’s best opportunities, including stocks, bonds, startups, venture funds, and more.

Partner with us

Unlock exciting business opportunities and growth potential.

Join Daba

Become a part of our vibrant community and enjoy exclusive benefits.

Contact us

Reach out to us for inquiries, support, or collaboration.
For Investor
StrategiesPortfolio ManagementAfrican Capital MarketsNews
Daba Pro Intelligence
For Capital Seekers
For StartupsFor Fund ManagersFor Private CompaniesFor Lenders
For Partners
Commercial BanksBroker DealersAsset ManagersInvestment BanksInvestment Advisors and ConsultantsLenders and Microfinance
Company
About UsMarket UpdatesEventsBlog and PodcastNewsletterCase StudiesAffiliate ProgramInvesting GlossaryOfficial ContactsTrust, Compliance and SecurityFrequently Asked Questions

Terms & ConditionsPrivacy Policy
EnglishEnglish

Owned by Daba Markets Inc. By using this site, you accept our Terms and Conditions and Privacy Policy. © 2024 All rights reserved. 2025 All rights reserved